Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were primarily mTOR-related stomatitis and asthenia at doses of ridaforolimus lower than expected, suggesting blockade of compensatory pathways in normal tissues. Six confirmed partial responses were reported (3 patients with breast cancer); 10 of 23 patients with breast cancer and 6 of 11 patients with ER+/high-proliferative breast cancer showed antitumor activity. Conclusions: Our study provides proof-of-concept that inhibiting the IGF1R compensatory response to mTOR inhibition is feasible with promising clinical activity in heavily pretreated advanced cancer, particularly in ER+/high-proliferative breast cancer (ClinicalTrials.gov identifier: NCT00730379). Clin Cancer Res; 21(1); 49–59. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 2×
“Thrombocytopenia 20 (23) 8 (9) 15 (33) 7 (16) Nausea 18 (21) 1 (1) 9 (20) 1 (2)”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“ORR with everolimus (10 mg every day) and the aromatase inhibitor exemestane (25 mg every day) compared with exemestane alone, strongly supporting the value of mTOR inhibition in patients with hormone receptor–positive breast cancer (32).”
BackgroundSelf-citationDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationAn integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 1×
“Furthermore, activation of compensatory pathways has also been observedwith other inhibitors of the PI3K–AKT–mTOR pathway, suggesting that it is a general mechanism of response to inhibition of this pathway and that concomitant blockade of these compensatory responses may be required for optimal therapeutic efficacy (…”
BackgroundSelf-citationLoboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-26 · Cited by 152 · cited 2×
“Activation of the RAS pathway has also been correlated with resistance to AKT inhibition (19).”
BackgroundMethodSelf-citation
Cited by
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
Gianferante, D. M., Mirabello, L., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 477
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205
Iams, W. T., & Lovly, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2518 · Cited by 179
“Dalotuzumab (MK-0646) SD 8%, PR 4%, CR 0% Di Cosimo et al., 2015 (36) I 87 Breast (26%), colorectal (22%), NSCLC (18%), sarcoma (16%), other (18”
BackgroundCombination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“estimated the efficacy of combined ridaforolimus and dalotuzumab for the treatment of breast cancer in human cell lines and mouse models, and the results of those studies led to the initiation of a phase I clinical trial [64].”
Metadata
- Authors
- Di Cosimo, S., Sathyanarayanan, S., Bendell, J. C., Cervantes, A., Stein, M. N., Braña, I., Roda, D., Haines, B. B., Zhang, T., Winter, C. G., Jha, S., Xu, Y., Frazier, J., Klinghoffer, R. A., Leighton-Swayze, A., Song, Y., Ebbinghaus, S., & Baselga, J.
- Venue
- Clinical Cancer Research
- Published
- 2015-01-01
- Volume
- 21
- Issue
- 1
- Pages
- 49-59
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2110189733
- Cited by
- 55
- References
- 7
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0940
- The paper
- Di Cosimo, S., Sathyanarayanan, S., Bendell, J. C., Cervantes, A., Stein, M. N., Braña, I., Roda, D., Haines, B. B., Zhang, T., Winter, C. G., Jha, S., Xu, Y., Frazier, J., Klinghoffer, R. A., Leighton-Swayze, A., Song, Y., Ebbinghaus, S., & Baselga, J. (2015). Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.